Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical...
Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject...
Everest Medicines’ Xerava NDA Accepted by Taiwan’s TFDA
Everest Medicines (HKG: 1952) announced that its New Drug Application (NDA) for Xerava (eravacycline) for...
China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...
HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the...
NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review
The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...
NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme
The National Healthcare Security Administration (NHSA) has announced the results of a special investigation, revealing...
FibroGen’s Roxadustat Sales in China Rise Despite Price Cut
US firm FibroGen Inc. (NASDAQ: FGEN), which operates subsidiaries in Beijing and Shanghai, released its...
Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study
China-based Inmagene Biopharmaceuticals and Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the...
Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...
BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...
Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial
China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...
Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study
Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...
Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...
Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...
GeneoDx Biotech’s Cervical Cancer Screening Kit Wins NMPA Approval
Shanghai GeneoDx Biotech Co., Ltd, a medical diagnosis unit of Sinopharm, has announced that it...
MicroPort CardioFlow Medtech’s VitaFlow Liberty and Angelguide Approved in Colombia
China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced...
HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy
China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...
Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion
Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...